PROKIDNEY CP (PROK)
(Real Time Quote from BATS)
$2.37 USD
+0.25 (11.79%)
Updated Apr 29, 2024 02:06 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for ProKidney Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 152 | 153 | 2 | 27 | 0 |
Income After Depreciation & Amortization | -152 | -153 | -2 | -27 | 0 |
Non-Operating Income | 22 | 6 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -129 | -147 | -2 | -27 | NA |
Income Taxes | 6 | 1 | 0 | 0 | NA |
Minority Interest | -100 | -40 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -135 | -148 | -2 | -27 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -35 | -108 | -2 | -27 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -148 | -150 | -2 | -26 | 0 |
Depreciation & Amortization (Cash Flow) | 4 | 3 | 0 | 1 | NA |
Income After Depreciation & Amortization | -152 | -153 | -2 | -27 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 61.71 | 61.54 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.57 | -0.23 | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.57 | -0.23 | -0.11 | NA | NA |
Fiscal Year end for ProKidney Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 24.21 | 46.62 | 39.82 | 40.88 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -24.21 | -46.62 | -39.82 | -40.88 |
Non-Operating Income | NA | 5.28 | 5.54 | 5.97 | 5.30 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -18.93 | -41.08 | -33.86 | -35.58 |
Income Taxes | NA | 2.79 | 0.91 | 0.97 | 1.33 |
Minority Interest | NA | -16.02 | -31.01 | -25.71 | -27.24 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -21.72 | -41.99 | -34.82 | -36.91 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.70 | -10.98 | -9.12 | -9.67 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 61.71 | 61.59 | 64.56 | 61.54 |
Diluted EPS Before Non-Recurring Items | NA | -0.09 | -0.18 | -0.14 | -0.16 |
Diluted Net EPS (GAAP) | NA | -0.09 | -0.18 | -0.14 | -0.16 |